Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS).

Q2 Medicine

Cardiovascular and Hematological Agents in Medicinal Chemistry Pub Date : 2021-01-01 DOI:10.2174/1871525718666200506095537

Nicolás R Robles, Rosa D Campillejo, Julian Valladares, Elena G de Vinuesa, Juan Villa, Guillermo Gervasini

{"title":"Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS).","authors":"Nicolás R Robles, Rosa D Campillejo, Julian Valladares, Elena G de Vinuesa, Juan Villa, Guillermo Gervasini","doi":"10.2174/1871525718666200506095537","DOIUrl":null,"url":null,"abstract":"Background and aims: Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the short-term effects of sacubitril- valsartan on the anemia of CRS.Methods: The study group comprised 39 patients with HFrEF, who were followed-up for three months. The study is a retrospective analysis of clinical data. Data of 3 months' and baseline visits were recorded including plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin, pro-BNP, and albuminuria.Results: In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101 ± 62 mg/day and 126 ± 59 mg/day at end. Mean hemoglobin increased from 12.2 ± 1.1 g/dl at baseline to 12.9 ± 1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI, 47.9-78.5%) at baseline and 38.4 (95%CI, 23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71 ± 1.0 to 2.48 ± 1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline 4.94 ± 0.60, three months visit 4.94 ± 0.61 mmol/l, p = 0.998).Conclusion: Sacubitril-valsartan improves anemia in CRS patients. An improvement in serum cystatin levels was observed. Few untoward effects were detected. These findings should be confirmed in wider clinical trials.","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"19 1","pages":"93-97"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Agents in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871525718666200506095537","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

Abstract

Background and aims: Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the short-term effects of sacubitril- valsartan on the anemia of CRS.

Methods: The study group comprised 39 patients with HFrEF, who were followed-up for three months. The study is a retrospective analysis of clinical data. Data of 3 months' and baseline visits were recorded including plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin, pro-BNP, and albuminuria.

Results: In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101 ± 62 mg/day and 126 ± 59 mg/day at end. Mean hemoglobin increased from 12.2 ± 1.1 g/dl at baseline to 12.9 ± 1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI, 47.9-78.5%) at baseline and 38.4 (95%CI, 23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71 ± 1.0 to 2.48 ± 1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline 4.94 ± 0.60, three months visit 4.94 ± 0.61 mmol/l, p = 0.998).

Conclusion: Sacubitril-valsartan improves anemia in CRS patients. An improvement in serum cystatin levels was observed. Few untoward effects were detected. These findings should be confirmed in wider clinical trials.

查看原文本刊更多论文

sacubitil -缬沙坦改善心肾综合征贫血(CRS)。

背景和目的:贫血是心力衰竭和慢性肾脏疾病(CKD)的常见并发症。sacubitil -缬沙坦是一种治疗慢性心力衰竭伴射血分数降低(HFrEF)的新疗法。我们评估了苏比里尔-缬沙坦治疗CRS贫血的短期效果。方法:研究组39例HFrEF患者，随访3个月。该研究是对临床资料的回顾性分析。记录3个月及基线就诊数据，包括血浆肌酐、肾小球滤过率、胱抑素C、血钾、血红蛋白、bnp前体和蛋白尿。结果:34例患者结束随访。基线时沙比替-缬沙坦平均剂量为101±62 mg/天，结束时为126±59 mg/天。平均血红蛋白从基线时的12.2±1.1 g/dl增加到12.9±1.0 g/dl (p = 0.001)。基线时贫血发生率为64.7% (95%CI, 47.9 ~ 78.5%)，随访后为38.4% (95%CI, 23.9 ~ 55.0%) (p = 0.016)。血清胱抑素C水平由2.71±1.0 mg/l降至2.48±1.0 mg/l (p = 0.028)。血清K水平保持不变(基线4.94±0.60,3个月随访4.94±0.61 mmol/l, p = 0.998)。结论:沙司比利-缬沙坦可改善CRS患者贫血。观察到血清胱抑素水平的改善。几乎没有发现不良影响。这些发现应该在更广泛的临床试验中得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Agents in Medicinal Chemistry Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Cardiovascular & Hematological Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal chemistry. Cardiovascular & Hematological Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cardiovascular & hematological drug discovery.